Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tango Therapeutics, Inc.TNGX · Entity 1497 | Chief Medical Officer | December 01, 2022 | December 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tango Therapeutics, Inc.
Report date December 01, 2022 · Filed December 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.73 · Expires 2032-12-01 | Direct | 350,000 |
Reported balance
After 2022-12-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-01 · Grant · Acquired 350,000 · Balance 350,000 F1: This option shall vest and become exercisable over a four-year period, at a rate of 25% on December 1, 2023, with the remaining option shares vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable over a four-year period, at a rate of 25% on December 1, 2023, with the remaining option shares vesting in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2022 Filed Dec 5, 2022 21:10 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0000899243-22-037607 · doc4.xml · derivative · entry 1 Weitzman Aaron · CIK 0001952088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2032-12-01 F1 · derivative.exercise_date: This option shall vest and become exercisable over a four-year period, at a rate of 25% on December 1, 2023, with the remaining option shares vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.